Influence of the long-acting beta 2-agonist indacaterol on the citric acid-induced cough model in conscious guinea pigs

T. Bouyssou, R. Bridgewater, P. Casarosa, M. Pieper, A. Schnapp, F. Gantner (Biberach an der Riß, Germany)

Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Session: Regulation of airway hyperresponsiveness and bronchodilators
Session type: Thematic Poster Session
Number: 1225
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Bouyssou, R. Bridgewater, P. Casarosa, M. Pieper, A. Schnapp, F. Gantner (Biberach an der Riß, Germany). Influence of the long-acting beta 2-agonist indacaterol on the citric acid-induced cough model in conscious guinea pigs. Eur Respir J 2010; 36: Suppl. 54, 1225

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs
Source: Annual Congress 2011 - Understanding disease and drug mechanisms
Year: 2011


PF-00610355 – an inhaled β2 adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction
Source: Annual Congress 2009 - Models of chronic airways disease and therapy
Year: 2009

The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD
Year: 2008


Effect of budesonide/formoterol, budesonide and terbutaline on exercise-induced bronchoconstriction in mild intermittent asthma
Source: Annual Congress 2011 - Asthma management and response
Year: 2011

Comparison of long acting β 2-agonist inhalers for treatment of exercise-induced bronchoconstriction (EIB)
Source: Eur Respir J 2003; 22: Suppl. 45, 312s
Year: 2003

Alpha-1L, but not alpha-1H, adrenoceptor antagonist prevents allergic bronchoconstriction in guinea pigs in vivo
Source: Eur Respir J 2001; 18: Suppl. 33, 104s
Year: 2001

The bronchodilator effects of the novel anti-inflammatory compound TPI 1020, alone and in combination with formoterol, in conscious guinea pigs
Source: Annual Congress 2009 - Preclinical models in drug development
Year: 2009


Inhalation of dry powder INS1009 (DP-INS1009) does not activate the cough reflex in guinea pigs: a comparison with nebulized treprostinil.
Source: International Congress 2017 – Experimental PH
Year: 2017


Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: the potential as a new asthma medication
Source: Annual Congress 2009 - Models of chronic airways disease and therapy
Year: 2009


Oesophageal stimulation with capsaicin did not affect citric acid-induced cough and specific airway resistance in awake guinea pigs
Source: Eur Respir J 2001; 18: Suppl. 33, 84s
Year: 2001

Effect of long-term treatment with inhaled furosemide and nedocromil sodium on exercise-induced broncho-obstruction in asthmatic children
Source: Eur Respir J 2001; 18: Suppl. 33, 495s
Year: 2001

Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline
Source: Eur Respir J 2002; 19: 865-871
Year: 2002



Effects of intratracheal pf-00610355, an inhaled β2 adrenoceptor agonist, in anaesthetised animals
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Effect of montelukast or salmeterol added to inhaled fluticasone on response to albuterol in children with exercise-induced bronchoconstriction
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009

Compound X – an inhaled β2 agonist with equivalent potency and superior duration of action (DOA)/ therapeutic index (TI) to salmeterol in the anaesthetised dog model of bronchoconstriction
Source: Annual Congress 2008 - Novel treatments for respiratory disease
Year: 2008

The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015


PF-3429281 – A novel inhaled dual antimuscarinic/β2 adrenoceptor agonist in the anaesthetised dog model of bronchoconstriction
Source: Annual Congress 2010 - Bronchodilators in airways disease
Year: 2010

The influence of combined nasal and esophageal stimulation on citric acid induced cough in guinea pigs
Source: Eur Respir J 2005; 26: Suppl. 49, 568s
Year: 2005

Effects of salmeterol, formoterol and placebo on pulmonary function and symptom recovery after histamine provocation in mild asthmatics
Source: Eur Respir J 2004; 24: Suppl. 48, 710s
Year: 2004

Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2-adrenoreceptor agonist
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009